Grünenthal Group: Grünenthal acquires testosterone

Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal's EBITDA in 2023.NebidoTM is the gold standard for the treatment

Related Keywords

Germany , Boston , Massachusetts , United States , Grunenthal , Nordrhein Westfalen , Japan , Switzerland , America , Swiss , Fabia Kehren , Gabriel Baertschi , Boston Area Community Health , Instagram , Bayer Ag , Linkedin , Grunenthal Group , Head External Communications Editorial Management , Latin America , Clinical Endocrinology , Head External Communications , Gr 252 Nenthal , Group , Cquires , Testosterone , Treatment , Debido , Rom , Player ,